CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 84% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Scan to Download iOS&Android APP

Trade 10x Genomics, Inc. - TXG CFD

51.43
8.07%
0.14
Low: 49.47
High: 51.79
Market Trading Hours* (UTC) Open now
Closes on Thursday at 21:00

Mon - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.14
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.030779 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.030779%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.013666 %
Charges from borrowed part ($-0.55)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.013666%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 47.48
Open* 49.47
1-Year Change* -48.43%
Day's Range* 49.47 - 51.79
52 wk Range 23.81-100.00
Average Volume (10 days) 1.10M
Average Volume (3 months) 26.78M
Market Cap 5.36B
P/E Ratio -100.00K
Shares Outstanding 114.46M
Revenue 503.71M
EPS -1.48
Dividend (Yield %) N/A
Beta 1.73
Next Earnings Date Feb 15, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Feb 1, 2023 47.48 1.51 3.28% 45.97 48.09 45.16
Jan 31, 2023 46.76 1.55 3.43% 45.21 47.00 44.96
Jan 30, 2023 45.27 -2.70 -5.63% 47.97 47.97 45.09
Jan 27, 2023 48.59 1.60 3.40% 46.99 48.73 46.87
Jan 26, 2023 47.99 0.98 2.08% 47.01 48.18 46.17
Jan 25, 2023 45.94 1.70 3.84% 44.24 45.98 43.17
Jan 24, 2023 45.44 -1.52 -3.24% 46.96 48.23 44.98
Jan 23, 2023 47.88 1.13 2.42% 46.75 49.34 46.37
Jan 20, 2023 47.28 2.41 5.37% 44.87 47.71 44.24
Jan 19, 2023 44.92 0.80 1.81% 44.12 45.26 43.48
Jan 18, 2023 45.55 1.59 3.62% 43.96 46.32 43.96
Jan 17, 2023 43.33 0.23 0.53% 43.10 44.79 42.17
Jan 13, 2023 43.15 2.33 5.71% 40.82 43.37 40.76
Jan 12, 2023 41.60 -0.36 -0.86% 41.96 42.07 39.55
Jan 11, 2023 41.91 0.64 1.55% 41.27 43.25 40.27
Jan 10, 2023 41.13 2.17 5.57% 38.96 42.26 38.92
Jan 9, 2023 39.99 2.03 5.35% 37.96 40.93 37.96
Jan 6, 2023 37.74 0.65 1.75% 37.09 38.30 34.80
Jan 5, 2023 37.53 2.25 6.38% 35.28 37.95 34.82
Jan 4, 2023 36.28 0.76 2.14% 35.52 36.67 34.73

10x Genomics, Inc. Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2017 2018 2019 2020 2021
Total revenue 71.085 146.313 245.893 298.845 490.49
Revenue 71.085 146.313 245.893 298.845 490.49
Cost of Revenue, Total 10.56 28.661 61.033 58.468 74.091
Gross Profit 60.525 117.652 184.86 240.377 416.399
Total Operating Expense 89.46 257.077 276.466 834.508 542.743
Selling/General/Admin. Expenses, Total 46.736 87.936 130.834 199.726 257.56
Research & Development 32.164 109.9 83.097 570.923 211.752
Other Operating Expenses, Total 0 30.58 1.502 1.27 -0.66
Operating Income -18.375 -110.764 -30.573 -535.663 -52.253
Interest Income (Expense), Net Non-Operating -0.503 -1.385 -0.274 -0.15 -0.66
Other, Net 0.137 -0.249 -0.186 1.337 -0.802
Net Income Before Taxes -18.741 -112.398 -31.033 -534.476 -53.715
Net Income After Taxes -18.762 -112.485 -31.251 -542.731 -58.223
Net Income Before Extra. Items -18.762 -112.485 -31.251 -542.731 -58.223
Total Extraordinary Items 0
Net Income -18.762 -112.485 -31.251 -542.731 -58.223
Income Available to Common Excl. Extra. Items -18.762 -112.485 -31.251 -542.731 -58.223
Income Available to Common Incl. Extra. Items -18.762 -112.485 -31.251 -542.731 -58.223
Diluted Net Income -18.762 -112.485 -31.251 -542.731 -58.223
Diluted Weighted Average Shares 93.8497 93.8497 39.0914 101.152 110.348
Diluted EPS Excluding Extraordinary Items -0.19992 -1.19857 -0.79943 -5.36552 -0.52763
Diluted Normalized EPS -0.19992 -1.19857 -0.79943 -5.33904 -0.52763
Unusual Expense (Income) 4.121 0
Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022
Total revenue 105.821 115.842 125.297 143.53 114.496
Revenue 105.821 115.842 125.297 143.53 114.496
Cost of Revenue, Total 17.06 4.915 24.518 27.598 25.478
Gross Profit 88.761 110.927 100.779 115.932 89.018
Total Operating Expense 116.037 126.17 141.176 159.36 156.231
Selling/General/Admin. Expenses, Total 55.704 68.503 62.076 69.877 66.675
Research & Development 41.883 53.402 54.582 61.885 64.078
Unusual Expense (Income) 1.2 0.2 0 0
Other Operating Expenses, Total 0.19 -0.85 0 0 0
Operating Income -10.216 -10.328 -15.879 -15.83 -41.735
Interest Income (Expense), Net Non-Operating -0.171 -0.151 -0.17 -0.168 0.441
Other, Net -0.729 0.521 -0.599 0.005 -0.4
Net Income Before Taxes -11.116 -9.958 -16.648 -15.993 -41.694
Net Income After Taxes -11.551 -11.052 -17.171 -18.449 -42.413
Net Income Before Extra. Items -11.551 -11.052 -17.171 -18.449 -42.413
Net Income -11.551 -11.052 -17.171 -18.449 -42.413
Income Available to Common Excl. Extra. Items -11.551 -11.052 -17.171 -18.449 -42.413
Income Available to Common Incl. Extra. Items -11.551 -11.052 -17.171 -18.449 -42.413
Diluted Net Income -11.551 -11.052 -17.171 -18.449 -42.413
Diluted Weighted Average Shares 108.714 109.866 110.874 111.913 112.966
Diluted EPS Excluding Extraordinary Items -0.10625 -0.1006 -0.15487 -0.16485 -0.37545
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.09908 -0.09941 -0.15487 -0.16485 -0.37545
  • Annual
  • Quarterly
2017 2018 2019 2020 2021
Total Current Assets 68.107 106.236 480.84 774.366 747.591
Cash and Short Term Investments 47.857 65.08 424.166 663.603 587.447
Cash & Equivalents 47.857 65.08 424.166 663.603 587.447
Total Receivables, Net 13.341 29.566 33.371 51.208 85.254
Accounts Receivable - Trade, Net 13.341 28.088 33.371 51.208 85.254
Total Inventory 4.838 8.57 15.27 29.959 59.966
Prepaid Expenses 2.071 3.02 8.033 13.029 13.896
Total Assets 75.609 124.31 605.923 929.341 1018.83
Property/Plant/Equipment, Total - Net 6.925 11.127 48.821 119.823 230.41
Property/Plant/Equipment, Total - Gross 17.958 25.21 67.876 150.325 279.431
Accumulated Depreciation, Total -11.033 -14.083 -19.055 -30.502 -49.021
Other Long Term Assets, Total 0.577 6.947 76.262 12.798 10.917
Total Current Liabilities 22.141 32.362 63.049 118.126 110.357
Accounts Payable 5.443 8.792 13.028 4.709 17.351
Accrued Expenses 8.959 12.118 30.035 92.326 75.821
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 4.224 4.187 9.882 0
Other Current Liabilities, Total 3.515 7.265 10.104 21.091 17.185
Total Liabilities 29.704 101.053 185.84 190.269 201.258
Total Long Term Debt 6.335 25.489 19.837 0 0
Long Term Debt 6.335 25.489 19.837 0
Other Liabilities, Total 1.228 43.202 102.954 72.143 90.901
Total Equity 45.905 23.257 420.083 739.072 817.568
Redeemable Preferred Stock 158.414 243.244 0
Common Stock 0.001 0.001 0.002 0.002 0.002
Additional Paid-In Capital 6.136 11.165 682.494 1544.22 1680.86
Retained Earnings (Accumulated Deficit) -118.631 -231.116 -262.367 -805.098 -863.321
Other Equity, Total -0.015 -0.037 -0.046 -0.05 0.022
Total Liabilities & Shareholders’ Equity 75.609 124.31 605.923 929.341 1018.83
Total Common Shares Outstanding 93.8497 93.8497 96.2416 108.486 112.515
Other Current Assets, Total 16.567 1.028
Intangibles, Net 22.354 25.397
Goodwill, Net 4.511
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total Current Assets 745.716 757.174 744.104 747.591 697.335
Cash and Short Term Investments 617.195 621.958 600.44 587.447 539.323
Cash & Equivalents 617.195 621.958 600.44 587.447 312.487
Total Receivables, Net 57.408 59.68 78.43 85.254 76.526
Accounts Receivable - Trade, Net 57.408 59.68 78.43 85.254 76.526
Total Inventory 38.507 44.087 51.141 59.966 63.697
Prepaid Expenses 14.442 13.298 14.065 13.896 17.762
Other Current Assets, Total 18.164 18.151 0.028 1.028 0.027
Total Assets 954.033 977.579 990.572 1018.83 1003.25
Property/Plant/Equipment, Total - Net 163.666 176.454 203.304 230.41 265.88
Property/Plant/Equipment, Total - Gross 198.415 215.665 247.698 279.431
Accumulated Depreciation, Total -34.749 -39.211 -44.394 -49.021
Goodwill, Net 4.511 4.511 4.511 4.511 4.511
Intangibles, Net 27.342 26.693 26.041 25.397 24.764
Other Long Term Assets, Total 12.798 12.747 12.612 10.917 10.761
Total Current Liabilities 120.549 113.126 100.375 110.357 94.446
Accounts Payable 15.578 16.181 17.037 17.351 18.956
Accrued Expenses 95.307 85.598 69.92 75.821 59.913
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 9.664 11.347 13.418 17.185 15.577
Total Liabilities 201.573 192.993 190.351 201.258 196.566
Total Long Term Debt 0 0 0 0 0
Long Term Debt 0
Other Liabilities, Total 81.024 79.867 89.976 90.901 102.12
Total Equity 752.46 784.586 800.221 817.568 806.685
Common Stock 0.002 0.002 0.002 0.002 0.002
Additional Paid-In Capital 1569.06 1612.23 1644.9 1680.86 1714.86
Retained Earnings (Accumulated Deficit) -816.649 -827.701 -844.872 -863.321 -905.734
Other Equity, Total 0.048 0.058 0.194 0.022 -2.443
Total Liabilities & Shareholders’ Equity 954.033 977.579 990.572 1018.83 1003.25
Total Common Shares Outstanding 109.589 110.74 111.537 112.515 113.276
Short Term Investments 226.836
  • Annual
  • Quarterly
2017 2018 2019 2020 2021
Net income/Starting Line -18.762 -112.485 -31.251 -542.731 -58.223
Cash From Operating Activities -10.699 -76.409 34.627 -217.898 -21.373
Cash From Operating Activities 4.305 3.905 7.066 14.012 21.118
Non-Cash Items 1.81 4.156 14.048 361.202 103.177
Cash Taxes Paid 0 -0.006 -0.022 0.28 8.66
Cash Interest Paid 0.658 1.824 2.25 1.67 1.222
Changes in Working Capital 1.948 28.015 44.764 -50.381 -87.445
Cash From Investing Activities -3.756 -6.709 -42.767 -38.394 -106.729
Capital Expenditures -3.756 -6.709 -42.767 -38.394 -101.278
Cash From Financing Activities 20.583 105.367 414.59 468.906 35.297
Financing Cash Flow Items 0 0 -5.848 -5.028
Issuance (Retirement) of Stock, Net 20.976 86.628 414.59 506.01 40.325
Issuance (Retirement) of Debt, Net -0.393 18.739 0 -31.256 0
Foreign Exchange Effects -0.014 -0.018 -0.045 -0.463 0.234
Net Change in Cash 6.114 22.231 406.405 212.151 -92.571
Other Investing Cash Flow Items, Total -5.451
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line -11.551 -22.603 -39.774 -58.223 -42.413
Cash From Operating Activities -4.082 -0.962 -27.178 -21.373 -20.802
Cash From Operating Activities 4.752 9.641 15.337 21.118 6.191
Non-Cash Items 17.922 47.188 74.717 103.177 28.014
Cash Taxes Paid 6.822 7.838 8.318 8.66 2.9
Cash Interest Paid 1.222 1.222 1.222 1.222 0.841
Changes in Working Capital -15.205 -35.188 -77.458 -87.445 -12.594
Cash From Investing Activities -44.316 -58.884 -79.111 -106.729 -257.558
Capital Expenditures -38.865 -53.433 -73.66 -101.278 -28.136
Other Investing Cash Flow Items, Total -5.451 -5.451 -5.451 -5.451 -229.422
Cash From Financing Activities 3.518 19.711 26.394 35.297 2.417
Financing Cash Flow Items -5.028 -5.028 -5.028 -5.028 -5.409
Issuance (Retirement) of Stock, Net 8.546 24.739 31.422 40.325 7.826
Issuance (Retirement) of Debt, Net 0 0 0 0
Foreign Exchange Effects 0.193 0.199 0.316 0.234 -0.018
Net Change in Cash -44.687 -39.936 -79.579 -92.571 -275.961
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Morgan Stanley Investment Management Inc. (US) Investment Advisor/Hedge Fund 10.0687 9625278 1765619 2022-09-30 LOW
Baillie Gifford & Co. Investment Advisor 8.9985 8602235 158847 2022-12-31 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 8.6396 8259122 446601 2022-09-30 LOW
Paladin Capital Management, LLC Investment Advisor 8.4859 8112208 0 2022-03-31
ARK Investment Management LLC Investment Advisor 4.5154 4316567 -260247 2022-12-31 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 4.1947 4009979 -152820 2022-09-30 LOW
Fidelity Management & Research Company LLC Investment Advisor 3.8495 3679934 -2314437 2022-09-30 LOW
Sands Capital Management, LLC Investment Advisor 3.5474 3391177 -135701 2022-09-30 LOW
SRS Investment Management, LLC Hedge Fund 3.1439 3005427 247182 2022-09-30 LOW
Generation Investment Management LLP Investment Advisor/Hedge Fund 2.7257 2605677 -22379 2022-09-30 LOW
Foresite Capital Management, LLC Private Equity 2.6189 2503528 0 2022-09-30 LOW
T. Rowe Price Associates, Inc. Investment Advisor 2.4038 2297942 959356 2022-09-30 LOW
Nikko Asset Management Co., Ltd. Investment Advisor/Hedge Fund 2.2783 2177988 -29270 2022-12-31 LOW
Credit Suisse Asset Management Investment Advisor/Hedge Fund 2.252 2152871 468859 2022-09-30 LOW
Brown Capital Management, LLC Investment Advisor 1.6895 1615093 -815862 2022-09-30 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 1.4267 1363917 26695 2022-09-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.3159 1257910 38393 2022-09-30 LOW
JP Morgan Asset Management Investment Advisor 1.2069 1153705 192745 2022-09-30 LOW
Meritech Capital Partners Venture Capital 1.1106 1061682 0 2022-09-30 LOW
Baillie Gifford Overseas Ltd. Investment Advisor 1.0824 1034693 -24110 2022-11-30 HIGH

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group
+485000+

Traders

65000+

Active clients monthly

$48000000+

Monthly investing volume

$28000000+

Withdrawn each month

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

10x Genomics, Inc. Company profile

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Industry: Laboratory Diagnostic & Testing Substances

6230 Stoneridge Mall Road
PLEASANTON
CALIFORNIA 94588
US

Income Statement

  • Annual
  • Quarterly

People also watch

XRP/USD

0.42 Price
+0.120% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 0.00329

Oil - Crude

76.14 Price
-0.860% 1D Chg, %
Long position overnight fee -0.0204%
Short position overnight fee 0.0049%
Overnight fee time 22:00 (UTC)
Spread 0.03

US100

12,765.20 Price
+2.470% 1D Chg, %
Long position overnight fee -0.0174%
Short position overnight fee 0.0068%
Overnight fee time 22:00 (UTC)
Spread 1.8

BTC/USD

23,883.45 Price
+0.540% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 60.00

Still looking for a broker you can trust?

Join the 480.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading